A Southwest Oncology Group Randomized Phase II Study of Doxorubicin and Paclitaxel as Frontline Chemotherapy for Women with Metastatic Breast Cancer

被引：0
作者：
Gary H. Lyman
Stephanie J. Green
Peter M. Ravdin
Charles E. Geyer
Christy A. Russell
Stanley P. Balcerzak
G. Thomas Budd
Silvana Martino
机构：
[1] University of Rochester Medical Center,James P. Wilmot Cancer Center
[2] University of Rochester School of Medicine,undefined
[3] Strong Memorial Hospital,undefined
[4] Southwest Oncology Group Statistical Center,undefined
[5] University of Texas Health Science Center,undefined
[6] University of Southern California,undefined
[7] Ohio State University,undefined
[8] Cleveland Clinic,undefined
[9] John Wayne Cancer Institute,undefined
来源：
Breast Cancer Research and Treatment | 2004年 / 85卷
关键词：
doxorubicin; metastatic breast cancer; paclitaxel; phase II; SWOG;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Purpose. To evaluate whether the high complete response (CR) rates for the combination of doxorubicin and paclitaxel in metastatic breast cancer observed in two European studies could be replicated in a multi-institutional cooperative group trial.
引用
收藏
页码：143 / 150
页数：7
相关论文
共 50 条
  • [31] A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline
    Ruey-Long Hong
    Ching-Hung Lin
    Tsu-Yi Chao
    Woei-You Kao
    Cheng-Hsu Wang
    Ruey Kuen Hsieh
    Wei-Shou Hwang
    Cancer Chemotherapy and Pharmacology, 2008, 61 : 847 - 853
  • [32] Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group
    Lueck, Hans-Joachim
    Du Bois, Andreas
    Loibl, Sibylle
    Schrader, Iris
    Huober, Jens
    Heilmann, Volker
    Beckmann, Matthias
    Staehler, Ann
    Jackisch, Christian
    Hubalek, Michael
    Richter, Barbara
    Stickeler, Elmar
    Eidtmann, Holger
    Thomssen, Christoph
    Untch, Michael
    Wollschlaeger, Kerstin
    Schuster, Tibor
    von Minckwitz, Gunter
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 139 (03) : 779 - 787
  • [33] Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy
    Rivera, E
    Holmes, FA
    Frye, D
    Valero, V
    Theriault, RL
    Booser, D
    Walters, R
    Buzdar, AU
    Dhingra, K
    Fraschini, G
    Hortobagyi, GN
    CANCER, 2000, 89 (11) : 2195 - 2201
  • [34] Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial
    ten Tije, AJ
    Smorenburg, CH
    Seynaeve, C
    Sparrebooma, A
    Schothorst, KLC
    Kerkhofs, LGM
    van Reisen, LGPM
    Stoter, G
    Bontenbal, M
    Verweij, J
    EUROPEAN JOURNAL OF CANCER, 2004, 40 (03) : 352 - 357
  • [35] Multicenter phase II trial of weekly paclitaxel for advanced or metastatic breast cancer: the Saitama Breast Cancer Clinical Study Group (SBCCSG-01)
    Sato, K
    Inoue, K
    Saito, T
    Kai, T
    Mihara, H
    Okubo, K
    Koh, J
    Mochizuki, H
    Tabei, T
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2003, 33 (08) : 371 - 376
  • [36] Phase II study of concurrent administration of doxorubicin and docetaxel as first-line chemotherapy for metastatic breast cancer
    Aihara, T
    Takatsuka, Y
    Itoh, K
    Sasaki, Y
    Katsumata, N
    Watanabe, T
    Noguchi, S
    Horikoshi, N
    Tabei, T
    Sonoo, H
    Hiraki, S
    Inaji, H
    ONCOLOGY, 2003, 64 (02) : 124 - 130
  • [37] Paclitaxel and Carboplatin as Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer: A Phase II Trial of the Hellenic Cooperative Oncology Group
    Gogas, Helen
    Pectasides, Dimitrios
    Kostopoulos, Ioannis
    Lianos, Evangelos
    Skarlos, Dimosthenis
    Papaxoinis, George
    Bobos, Mattheos
    Kalofonos, Haralabos P.
    Petraki, Kalliopi
    Pavlakis, Kitty
    Bafaloukos, Dimitrios
    Fountzilas, George
    CLINICAL BREAST CANCER, 2010, 10 (03) : 230 - 237
  • [38] Phase II Study of Weekly Paclitaxel for Advanced or Metastatic Breast Cancer in Japan
    Horiguchi, Jun
    Rai, Yoshiaki
    Tamura, Kazuo
    Taki, Toshihiko
    Hisamatsu, Kazufumi
    Ito, Yoshinori
    Seriu, Taku
    Tajima, Tomoo
    ANTICANCER RESEARCH, 2009, 29 (02) : 625 - 630
  • [39] Paclitaxel and epidoxorubicin or doxorubicin versus cyclophosphamide and epidoxorubicin as first-line chemotherapy for metastatic breast carcinoma:: A randomised phase II study
    Gebbia, V
    Blasi, L
    Borsellino, N
    Caruso, M
    Leonardi, V
    Agostara, B
    Valenza, R
    ANTICANCER RESEARCH, 2003, 23 (1B) : 765 - 771
  • [40] PHASE-II TRIAL OF AMONAFIDE IN ADVANCED PANCREAS CANCER - A SOUTHWEST-ONCOLOGY-GROUP STUDY
    LEICHMAN, CG
    TANGEN, C
    MACDONALD, JS
    LEIMERT, T
    FLEMING, TR
    INVESTIGATIONAL NEW DRUGS, 1993, 11 (2-3) : 219 - 221
12345